Zionexa
Founded in 2018, we are an international leader in the development of in-vivo biomarkers to guide targeted therapies in oncology. Zionexa is an international and innovative company developing and commercializing molecular imaging solutions, in-vivo biomarkers for targeted therapies in oncology, to improve patients’ pathway and bring them a better quality of life.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Clinical Services
- Market Focus:
- Internationally (various countries)
About us
We are dedicated to developing in-vivo biomarkers to guide targeted therapies for precision medicine. In-vivo biomarkers ensure a personal diagnosis for every patient, a selection of an effective treatment, as well as a therapy monitoring.
Molecular imaging is a non-invasive technique which allows healthcare professionals to visualize molecules and their function within the cell. Molecular imaging is used for initial diagnosis and monitoring of cancer tumors.
In 2018, 18.1 million new cancer cases have been reported in the world. Everyday, we work to develop biomarkers specialized in oncology to improve the patient’s pathway and quality of life.
Our team is composed of international experts who have more than 20 years of experience in radiopharmaceutical industry and molecular imaging.